235results about "Chlorine active ingredients" patented technology

The invention discloses a quick and long-acting gynecological antibacterial gel and a preparation method thereof. According to the formula of the gynecological antibacterial gel, a plurality of key components are selected and combined, and the gynecological antibacterial gel specifically comprises the following components in parts by weight: 5-15 parts of poloxamer, 0.5-1 part of carbomer, 0.5-1 part of N, N-dicarboxymethyl alanine trisodium salt, 0.2-0.1 part of carboxymethyl cellulose and 50-250ppm stable chlorine dioxide powder. The preparation method of the gynecological antibacterial gel comprises the five steps of chlorine dioxide chelating solution preparation, gel matrix preparation, gel forming, pH value adjustment and finished product packaging, all the steps are accurately controlled, and the product quality is ensured. The invention provides a gynecological gel product which is high in initial flowability, can be quickly gelated in vivo and has a quick long-acting antibacterial function, solves the problems of non-ideal antibacterial effect, inconvenience in use, insufficient safety and the like of an existing gynecological nursing product, ensures the safety and stability of the product, overcomes many defects of a traditional product, and has a good application prospect. And a better choice is provided for female reproductive health care.

Provided herein are methods and compositions for the treatment of ALS using chlorite or a pharmaceutical composition comprising sodium chlorite, for a target ALS patient population. Also provided herein are methods for identifying a target ALS patient population likely to be responsive to treatment with chlorite or a pharmaceutical composition comprising sodium chlorite, the methods including identifying ALS patients with elevated plasma C-reactive protein (CRP) levels and / or patients age 40-65, sporadic ALS pathology, or combinations thereof.

Provided is a method for producing a chlorous acid water preparation in which chlorous acid water, chlorous acid as a main effective component thereof, and chlorine peroxide radicals as active molecular species thereof have been more efficiently stabilized in the liquid at ordinary temperature in high and low concentrations. The method is for producing a chlorous acid water preparation having a predetermined content (in terms of chlorous acid (HClO2=68.46)), and comprises: (1) preparing a buffer solution; (2) obtaining the concentration of the buffer solution; (3) preparing chlorous acid water; (4) obtaining a content in the chlorous acid water (in terms of chlorous acid (HClO2=68.46)); (5) obtaining an amount of the buffer solution required for dilution, from the content in the chlorous acid water (in terms of chlorous acid (HClO2=68.46)) and the predetermined content (in terms of chlorous acid (HClO2=68.46)); and (6) diluting the chlorous acid water with said amount of the buffer solution to produce a chlorous acid water preparation having the predetermined content (in terms of chlorous acid (HClO2=68.46)).

A treatment system for a microbial infection including a solution having a source of ions in the amount of about 25-225 mM, and a source of an oxidizing agent in the amount of about 25-225 mM, water, and a delivery device comprising polysaccharide(s) forming a three-dimensional polymeric biphasic network housing the solution.

Described herein are methods using chlorite formulations to affect stem cell activity.

The present application refers to an electrochemically activated salt solution (EGAS), its production, and its use for treating infections.

Disclosed in the present invention are a pharmaceutical chlorine dioxide antimicrobial liquid agent, a preparation method therefor, and use thereof. The pharmaceutical chlorine dioxide antimicrobial liquid agent comprises: a solvent and chlorine dioxide gas infused into the solvent, wherein the concentration of chlorine dioxide in the pharmaceutical chlorine dioxide antimicrobial liquid agent is 5000 mg / L-10000 mg / L. According to the pharmaceutical chlorine dioxide antimicrobial liquid agent, the preparation method therefor, and the use thereof provided by the present invention, the obtained pharmaceutical chlorine dioxide antimicrobial liquid agent has high concentration, good stability, and high purity, meeting the requirements for the use of the pharmaceutical chlorine dioxide antimicrobial liquid agent as a pharmaceutical product.

Systems and methods for disinfecting a surface including a liquid irrigator and a hypochlorous acid generator assembly that is functionally coupled to the liquid irrigator. The liquid irrigator includes a pump mechanism and an applicator. The hypochlorous acid generator assembly is designed to produce a hypochlorous acid solution and maintain the solution within a targeted pH range in a reservoir. The pump mechanism of the liquid irrigator withdraws fluid from the reservoir and delivers an effective amount of the hypochlorous acid solution to a surface to be treated via the applicator. The hypochlorous acid solution is prepared on-site and immediately prior to application, ensuring maximum efficacy and freshness.

The invention belongs to the technical field of biochemistry and medicine, and particularly relates to skin gel containing chemically modified lysozyme as well as a preparation method and application of the skin gel. According to the invention, chlorine dioxide is combined with the lysozyme in a chemical chelation manner, so that the antibacterial activity and stability of the modified lysozyme can be effectively improved. Through the innovative technical scheme, the chlorine dioxide chelate and the lysozyme can be effectively combined, so that the chlorine dioxide chelate and the lysozyme play a synergistic role to effectively enhance the antibacterial property of the modified lysozyme and improve the stability of the lysozyme in different environments, the defects in the traditional lysozyme application are effectively overcome, and the application potential of the lysozyme is improved; meanwhile, a new field is opened up for efficient application of chlorine dioxide.

A biofilm treatment system including a delivery device housing a composition having a source of ions in the amount of about 25-225 mM and a source of an oxidizing agent in the amount of about 25-225 mM and a source of Vitamin C in the amount of about 1 mM to 10 mM, the composition being configured as a biofilm reducer.

Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.

The present specification discloses compositions comprising, consisting essentially of, or consisting of hypochlorous acid or free chlorine in combination with one or more metal particles, one or more metal salts, or any combination thereof. The present invention also discloses kits comprising, consisting essentially of, or consisting of one or more containers containing the compositions disclosed herein or the ingredients that make up the compositions, as well as methods and uses for the compositions and kits.

The present specification discloses a method of making a composition stably comprising one or more peroxides and one or more free available chlorine species, one or more peroxide for use in the manufacture of a composition stably comprising one or more peroxides and one or more free available chlorine species, as well as formulated compositions using a composition manufactured according to a method or use disclosed herein.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

Disclosed herein are methods for making compositions stably comprising one or more peroxides and one or more free available chlorine species, one or more peroxides for use in making compositions stably comprising one or more peroxides and one or more free available chlorine species, and compositions formulated using compositions made according to the methods or uses disclosed herein.

The present invention may be directed to compositions and methods for the treatment of alopecia / epilation, which may include the treatment of alopecia conditions. Compositions and methods relate to oral supplements of oral minoxidil, including an SLC22A9 inducer, an HIF-alpha inducer, and / or an acidulant. Acidification of blood in patients with alopecia may cause mild acidosis, which may up-regulate SLC22A9 and / or down-regulate AABC3. Inducing SLC22A9, inducing HIF-alpha, and / or acidifying the patient's blood can promote oral form of minoxidil into hair follicles.

The present invention relates to the technical field of veterinary medicine, and specifically discloses a composition for treating cow mastitis and a preparation method thereof. The composition includes: 0.5 part-2 parts of a composite sodium chlorite effervescent tablet, 1.2 parts-1.5 parts of puerarin, 1.8 parts-2.0 parts of a chitosan-derived quaternary ammonium salt, 1 part-5 parts of modified nano zinc oxide, 2 parts-6 parts of magnesium-aluminum hydrotalcite, 1.6 parts-3 parts of an antibacterial agent, 5 parts-10 parts of a film former, 2 parts-4 parts of a plasticizer, 3 parts-7 parts of a surfactant, 1 part-2 parts of a thickener, and 550 parts-650 parts of distilled water. The composition provided by the present invention can fundamentally treat and prevent cow mastitis under the synergistic effect of each component, with a cure rate of more than 90%, and will not cause drug residues, thereby avoiding the generation of drug residues and bacterial resistance problems in cow's milk. The composition is suitable for promotion in animal husbandry and has broad application prospects.

This invention relates to the field of biomedicine and hygiene disinfection products technology, and discloses a method for preparing a slightly acidic oxidizing potential hydrogel. The gel is made from slightly acidic oxidizing potential water and an inorganic gelling agent, lithium magnesium silicate. The preparation method includes: separately preparing strongly acidic oxidizing potential water and alkaline reducing potential water by electrolysis; mixing the two online in a preset ratio; adjusting the pH value to 5.0 to 6.5 through a neutralization reaction; subsequently adding lithium magnesium silicate; and then dispersing the mixture through high-speed shearing and sealing for static swelling to form a gel. This invention solves the problems of easy decomposition of available chlorine and gel liquefaction by utilizing an inorganic gel system, resulting in a gel with high stability and a long shelf life. This product solves the problem of easy loss of liquid disinfectants, prolongs the bactericidal effect time on wounds and oral ulcers, and is non-irritating and non-sensitizing to the skin, making it suitable for long-term disinfection of hands, skin, and mucous membranes.

To provide a coronavirus killing agent.SOLUTION: The present disclosure provides coronavirus killing agents. In particular, the present disclosure provides a coronavirus disinfectant comprising a chlorous acid aqueous solution. In particular, the present disclosure provides a method for killing or disinfecting coronavirus using a chlorous acid aqueous solution. The concentration of free chlorine (assuming Cl = 35.45) in a chlorous acid aqueous solution can be at least 5ppm or higher in the absence of organic matter. The content of chlorous acid in the chlorous acid aqueous solution (HClO2 = 68.46) can be at least 200ppm or more under the presence of organic matter including disinfection of hands and the like. The coronavirus may be SARS coronavirus (SARS-CoV), MERS coronavirus (MERS-CoV), or 2019 novel coronavirus (SARS-CoV-2).SELECTED DRAWING: None

To provide a disinfectant composition that provides excellent cleaning and disinfection of medical devices.SOLUTION: A disinfectant composition comprising hypochlorous acid in an amount of at least 725 ppm and up to 1,200 ppm, or free available chlorine in an amount of at least 725 ppm and up to 1,200 ppm, and 2-1) one or more metal oxide particles present in an amount of 10 ppm to 300 ppm, the one or more metal oxide particles including copper, iron, titanium, zinc, or a mixture thereof; or 2-2) one or more metal oxide salts present in an amount of 10 ppm to 300 ppm, the one or more metal oxide salts including a metal acetate, a metal chloride, or a metal nitrate, the one or more metal oxide salts including a salt of copper and a salt of zinc.SELECTED DRAWING: None

Methods and systems and related compositions, matrices and devices, for timed and / or targeted administration of chlorate for treatment and / or prevention of infections of a biological environment and related compositions, devices, matrices and implants. Chlorate administration can be performed alone or in combination with an antibiotic in a location and / or time targeted manner, the concentration and use of the chlorate and / or the antibiotic agents depending on the oxic / hypoxic / anoxic condition of the area being treated.

A wound irrigation system includes a first fluid including an ion rich compound having free available ions; and a second fluid including an oxidation-reduction potential increasing compound, the second fluid housed separately from the first fluid. Mixing the first and second fluids in a charging area forms an ionically charged fluid with an oxidation-reduction potential higher than a wound site oxidation-potential. The ionically charged fluid increases antimicrobial activity of the wound upon application.

The present invention is directed to oral pharmaceutical compositions comprising at least one statin and at least one antiseptic and / or antibacterial agent. Likewise, it is aimed at their use to prevent and / or treat diseases of the soft tissues present in the oral cavity, such as periodontal disease. A method is also described for preventing and / or treating diseases of the soft and hard tissues surrounding the tooth present in the oral cavity that comprises administering said pharmaceutical composition.

Provided herein are apparatus and methods for production of a chlorite salt, e.g., sodium chlorite, based on purification by recrystallization to achieve the desired purity.

Provided are anti-microbial compositions that include an aqueous solution of hypochlorous acid encapsulated in a nanoparticle that allows for controlled release of hypochlorous acid. Also provided are methods of making and using such compositions.

A method of monitoring and treating a subject with ALS based on biomarkers. In some embodiments, the method comprises: identifying that a subject has a ratio of LPS1EGF associated with ALS; and based on the identifying that the subject has the ratio of LPS:EGF associated with ALS, determining that the subject is eligible for sodium chlorite therapy for the ALS, determining based on the ratio of LPS:EGF whether to continue the therapeutic regimen of sodium chlorite; wherein the ratio of LPS:EGF in the subject is no greater than 50 and the therapeutic regimen of sodium chlorite is about 0.2 mg / kg / day to about 3.5 mg / kg / day administered orally and / or parenterally.

Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Q), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.